Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361802412> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4361802412 abstract "IN PATIENTS WITH MULTIPLE SCLEROSIS USING OCRELIZUMAB
 SEROLOGICAL STATUS OF HEPATITIS B VIRUS
 
 Abstract
 Objective
 B-cell depleting treatments are associated with potential risks of viral infections. Hepatitis B virus (HBV) infection is the most common chronic viral infection and it is estimated that 30% of the world population has serological evidence of current or past infection
 Material end methods
 Our study is a single-center, retrospective, cross-sectional study. We retrospectively reviewed the clinical records of MS patients receiving ocrelizumab. Demographic and clinical characteristics of patients, Expanded Disability Status Scale (EDSS), drug history before ocrelizumab for MS; Mean ocrelizumab intake times, smoking status, hepatitis C virus, HIV serological status, HBV serological status, HBV treatment status were recorded.
 Results
 The study included 64 MS patients treated with ocrelizumab. The mean age was 41.6±9.8 years (min-max: 21-62 years). 75% of the cases were female (n:48), 25% were male (n:16).
 HIV and hepatitis C virus serological tests were negative in all cases. HBsAg was found to be positive in 1.6% (n:1) and Anti-HBcIgG in 12.5% (n:8). The number of patients who were started on hepatitis B treatment was 12.5% (n:8), and tenofovir disoproxil was started in 2 patients (25%), entecavir in 5 patients (62.5%), and tenofovir alafenamide in 1 patient (12.5). The mean duration of taking ocrelizumab for the patients was 28.5±13.1 months (min-max: 6-46 months).
 Conclusion
 In conclusion, all patients should be screened for HBV before starting ocrelizumab therapy. Both HBsAg and Anti-HBcIg G tests should be used. The isolated presence of Anti-HBcIg G may cause HBV reactivation. Therefore, Anti-HBcIg G should be screened before immunosuppressive therapy." @default.
- W4361802412 created "2023-04-05" @default.
- W4361802412 creator A5024829350 @default.
- W4361802412 creator A5068331391 @default.
- W4361802412 date "2022-09-13" @default.
- W4361802412 modified "2023-09-26" @default.
- W4361802412 title "OCRELİZUMAB KULLANAN MULTİPL SKLEROZ HASTALARINDA HEPATİT B VİRÜSÜ SEROLOJİK DURUMU" @default.
- W4361802412 cites W1969776963 @default.
- W4361802412 cites W2064531937 @default.
- W4361802412 cites W2125474736 @default.
- W4361802412 cites W2883892074 @default.
- W4361802412 cites W2905652667 @default.
- W4361802412 cites W3057331636 @default.
- W4361802412 cites W3186665807 @default.
- W4361802412 cites W3211374349 @default.
- W4361802412 cites W4212899519 @default.
- W4361802412 doi "https://doi.org/10.17517/ksutfd.1158614" @default.
- W4361802412 hasPublicationYear "2022" @default.
- W4361802412 type Work @default.
- W4361802412 citedByCount "0" @default.
- W4361802412 crossrefType "journal-article" @default.
- W4361802412 hasAuthorship W4361802412A5024829350 @default.
- W4361802412 hasAuthorship W4361802412A5068331391 @default.
- W4361802412 hasBestOaLocation W43618024121 @default.
- W4361802412 hasConcept C126322002 @default.
- W4361802412 hasConcept C159654299 @default.
- W4361802412 hasConcept C203014093 @default.
- W4361802412 hasConcept C2522874641 @default.
- W4361802412 hasConcept C2776175608 @default.
- W4361802412 hasConcept C2777382497 @default.
- W4361802412 hasConcept C2777410769 @default.
- W4361802412 hasConcept C2777869810 @default.
- W4361802412 hasConcept C2780593183 @default.
- W4361802412 hasConcept C2908647359 @default.
- W4361802412 hasConcept C45189115 @default.
- W4361802412 hasConcept C71924100 @default.
- W4361802412 hasConcept C90924648 @default.
- W4361802412 hasConcept C99454951 @default.
- W4361802412 hasConceptScore W4361802412C126322002 @default.
- W4361802412 hasConceptScore W4361802412C159654299 @default.
- W4361802412 hasConceptScore W4361802412C203014093 @default.
- W4361802412 hasConceptScore W4361802412C2522874641 @default.
- W4361802412 hasConceptScore W4361802412C2776175608 @default.
- W4361802412 hasConceptScore W4361802412C2777382497 @default.
- W4361802412 hasConceptScore W4361802412C2777410769 @default.
- W4361802412 hasConceptScore W4361802412C2777869810 @default.
- W4361802412 hasConceptScore W4361802412C2780593183 @default.
- W4361802412 hasConceptScore W4361802412C2908647359 @default.
- W4361802412 hasConceptScore W4361802412C45189115 @default.
- W4361802412 hasConceptScore W4361802412C71924100 @default.
- W4361802412 hasConceptScore W4361802412C90924648 @default.
- W4361802412 hasConceptScore W4361802412C99454951 @default.
- W4361802412 hasLocation W43618024121 @default.
- W4361802412 hasOpenAccess W4361802412 @default.
- W4361802412 hasPrimaryLocation W43618024121 @default.
- W4361802412 hasRelatedWork W1984475196 @default.
- W4361802412 hasRelatedWork W2028125236 @default.
- W4361802412 hasRelatedWork W2159602954 @default.
- W4361802412 hasRelatedWork W2160193513 @default.
- W4361802412 hasRelatedWork W2314594618 @default.
- W4361802412 hasRelatedWork W2377681251 @default.
- W4361802412 hasRelatedWork W2771386081 @default.
- W4361802412 hasRelatedWork W2942979299 @default.
- W4361802412 hasRelatedWork W3136868089 @default.
- W4361802412 hasRelatedWork W3201360696 @default.
- W4361802412 isParatext "false" @default.
- W4361802412 isRetracted "false" @default.
- W4361802412 workType "article" @default.